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Introduction
Lung cancer represents the most frequent cause of
death due to a neoplastic disease, the most frequent
malignant tumour in the world and in Poland the most
frequent malignant tumour in males [1-3]. The high
mortality which accompanies neoplastic disease is
ascribed mainly to the spread of cancerous cells [4,5].
Role of angiogenesis in development of neoplastic
metastases has been relatively well recognised while
the role of lymphangiogenesis in the process remains
incompletely clarified [6,7]. Studies on animal models
suggest that tumour lymphangiogenesis plays leading
role in the metastatic process [8].
Structure of lymphatic vessels promotes dissem-
ination of tumour cells. They represent thin-walled,
low pressure vessels, which transport intercellular
fluid, proteins, lymphocytes and antigen-presenting
cells to lymph nodes and to circulation. On the other
hand, blood vessels work under higher internal pres-
sures and their wall in thicker [9]. Neoplastic cells
which penetrate lymphatic vessels may be passed to
the circulation by the thoracic duct or by side anas-
tomoses (leaks), probably existing in the tumour
structure between blood and lymphatic systems
[10]. 
Role of lymphangiogenesis, probably responsi-
ble also for metastases in a neoplastic disease has
provided topic of few reports in the recent decade.
This reflected, among other, the absence of specific
markers which might specifically identify lymphat-
ic vessels.
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Abstract: Lung cancer represents one of the most frequent causes of death due to neoplastic disease in Poland and around
the world. The high mortality which accompany neoplastic diseases used to be ascribed mainly to dissemination of cancer-
ous cells. Studies on animal models suggest that tumour lymphangiogenesis represents the principal factor in the process of
metastases formation. Lymphangiogenesis involves a process of formation of new lymphatic vessels from already existing
lymphatic capillaries. Lymphangiogenesis is stimulated by vascular endothelial growth factors (VEGF) and other, recently
reported factors, such as, e.g., cyclooxygenase 2, fibroblast growth factor 2, angiopoetin-1 and the insulin-resembling
growth factor. In lymphangiogenesis a key role is played by neutropilin 2 or podoplanin and this promoted development of
studies on lymphangiogenesis. Activation of VEGF-C/VEGF-D/VEGFR-3 axis increases motility and invasiveness of neo-
plastic cells, promotes development of metastases in several types of tumours such as, e.g., lung cancer, mammary carcino-
ma, cancers of the neck, prostate and large intestine.  In recent years lymphangiogenesis provided topic of many studies. A
positive correlation was detected between expressions of VEGF-C/D and VEGFR-3 in non-small cell lun cancer. In patients
with lung cancer with high expression of VEGF-C a markedly abbreviated survival was noted. Positive correlation was
detected between expression of VEGF-C and VEGF-D on one hand and expression of LYVE-1 on the other in sentinel
lymph nodes with metastases of neoplastic cells in patients with non-small cell lung cancer. Also, high density of lymphat-
ic vessels and high density of intraneoplastic microvessels proved to be independent poor prognostic indices in patients with
non-small cell lung cancer. Extensive hope is linked to studies on inhibitors of lymphangiogenesis, which may improve
results of treatment also in tumour patients.
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Review article
Structure and function of lymphatic system 
The lymphatic system was described for the first time
by Gasparo Aselli in 1627. In 1902, Florence Sabin
advanced a theory related to formation of lymphatic
system during embryogenesis. According to the theo-
ry, peripheral lymphatic system developed from prim-
itive lymphatic vesicles, arising due to budding of of
venous endothelial cells. The report of 2002, published
by Jussila and Alitalo, confirmed the theory of Sabin
[11]. The lymphatic system consists of thin-walled,
low pressure vessels, lymph nodes localised along the
vessels, lymphoid organs such as the spleen and the
thymus and of circulating lymphocytes [12]. Due to
the control of intercellular fluid transport, the lym-
phatic system maintains an appropriate plasma vol-
ume, prevents against pressure build-up in tissues and
plays a significant role in the immune defence system
of the body [13].
Lymphatic vessels differ in their function and
structure from those of blood vessels. Walls of lym-
phatic vessels are thin, cytoplasm of endothelial cells
is less dense, basement membrane is discontinuous,
which increases permeability of the vessels. Lumen of
lymphatic vessels shows a three-fold higher diameter
than lumen of small blood vessels, shape of lymphatic
vessels is less regular and the vessels may be occluded
(frequently collapsed) [14]. The wall of lymphatic ves-
sels is joined to the extracellular matrix by reticular and
collagen fibres. With an increasing inflow of intercellu-
lar fluid and in conditions of an increased pressure the
connective tissue fibres stretch to open vascular lumen
[15]. Lymph flow is facilitated by contractions of
smooth muscles which surround the vessels and a direc-
tion of flow is enforced by the system of valves in lym-
phatic vessels [14]. Destruction or a disturbed continu-
ity of lymphatic vessels by infectious, mechanical
agents, obliteration, irradiation, or surgical procedures
lead to oedema in the lymphatic system and to increased
pressure in the surrounding tissues [16].
Markers of lymphatic vessels 
Lymphangiogenesis involves a process of new lym-
phatic vessel formation from the already existing lym-
phatic capillaries [17]. Progress in studies on lym-
phangiogenesis was hampered due to the lack of spe-
cific markers of lymphatic system. In the past, imaging
of lymphatic vessels was restricted to techniques
linked to administration of specific dyes to the lym-
phatic system. The dyes used at present, e.g. Evans
blue or trypan blue are much better tolerated than those
used in the past [14]. The dyes and rhodamine dextran
are routinely applied in studies on animals [18]. Until
now, immunohistochemical identification of lymphat-
ic vessels was possible due to comparison of expres-
sion of endothelial markers with those of basement
membrane. For example, CD31, the expression of
which is observed in blood and lymphatic vessels was
used in combination with markers of basement mem-
brane and collagen type IV [19]. The vessels which
were labelled with CD31-specific antibodies but with-
out expression of basement membrane proteins and
containing no erythrocytes in their lumen, were taken
as representing lymphatic vessels [20]. Use of a spe-
cific marker of blood vessels, PAL-E, in combination
with PECAM-1 (platelet/endothelial cell adhesion
molecule-1), was also helpful in identification of lym-
phatic vessels [21]. 
It was not until the recent few years that more
numerous reports on lymphangiogenesis appeared.
This was linked to distinguishing specific proteins
which manifest expression in lymphatic vessels and to
discovery of factors which control and stimulate
growth of lymphatic vessels [22].
The recently discovered receptor for hyaluronic
acid, located in endothelium of lymphatic vessels,
LYVE-1 (lymphatic endothelium hyaluronate recep-
tor) represents an important marker of lymphatic ves-
sels [23] (Fig. 1). LYVE-1 plays a key role not only in
metabolism, binding and transport of hyaluronic acid
from tissues to lymphatic vessels but also in
transplacement of leukocytes in lymphatic vessels and
lymph nodes [24]. LYVE-1 in 41% manifests a struc-
ture homologous to CD44 molecule, the expression of
which is accompanied by an elevated metastatic poten-
tial of tumour cells [25]. Expression of LYVE-1 is
observed also in hepatic sinuses and in splenic
endothelium [24,26,27]. Until now, LYVE-1 has not
been detected in any non-sinusoidal vascular endotheli-
um except of blood vessels in lungs [28] and in lymph
nodes [27]. Expression of LYVE-1 in lymph nodes is
not restricted to lymphatic vessels and sinuses but it is
also present in high endothelium venules (HEV) [27].
Cells of the endothelium exhibit a cuboid or cylindrical
shape, they are high and typically protrude to the lumen
of the vessel. In this respect they are basically different
from endothelial cells in other blood vessels [29,30].
Moreover, HEV represent the site in which lymphocytes
emigrate from peripheral blood [31]. 
Another marker of lymphatic vessels involves the
human transcription factor, Prox-1. It was identified
for the first time in 1999 as a molecule which under-
goes expression in cells of lymphatic endothelium.
Prox-1 is involved in growth and elongation of lym-
phatic capillaries [32]. 
Another protein which is expressed in a mature
lymphatic endothelium is neutropilin 2 (NRP2). The
protein is a receptor which binds VEGF-C (vascular
endothelial growth factor) and also plays role of a co-
receptor for VEGFR-3 (the receptor for VEGF) [33].
An additional protein which is typical for lym-
phatic endothelium involves podoplanin, belonging
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to the group of mucoproteins, the expression of which
in endothelial cells of lymphatic vessels is controlled
by Prox-1 [34]. Recently conducted studies indicate
that podoplamin may participate in adhesion and
migration of lymphatic endothelium cells [35].
Characterization of the proteins resulted not only in
a design of novel techniques of identifying lymphatic
vessels but permitted also to suggest a new approach to
a lymphangiogenesis-modifying therapy of diseases
associated with an abnormal structure and/or function
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Fig. 1. Expression of LYVE-1 (brown) in lymphatic vessels in non-small cell lung cancer. A – magnification ×400; B – magnification ×100.
of lymphatic vessels [36]. Currently, a great challenge
is linked to definition of the detailed role played by
LYVE-1 and other proteins engaged in immunological
function of lymphoid system and recognition of the
ways in which tumour cells take advantage of lym-
phatic vessels for development of metastases and,
thus, for progression of the tumour. 
Factors which stimulate lymphangiogenesis
Vascular endothelial growth factors (VEGF) are glyco-
proteins, the family of which encompasses VEGF-A,
VEGF-B, VEGF-C, VEGF -D, VEGF- E and Placenta
Growth Factor (PIGF) [37].
The vascular endothelial growth factor (VEGF),
earlier termed the vascular permeability factor (VPF),
capable of increasing vascular permeability, was dis-
covered in 1989 and plays an important role in control
of the of angiogenesis process [38, 39]. All proteins of
the VEGF family stimulate cell-mediated immunity by
binding to their receptors (VEGFR), located on the
surface of endothelial cells. VEGFR receptors consist
each of the extracellular, transmembrane and intracel-
lular domain, the latter manifesting activity of tyrosine
kinase [40].
VEGF-A encompasses 10 isoforms: VEGF-A121,
VEGF-A138, VEGF-A145, VEGF-A148, VEGF-A162,
VEGF-A162b, VEGF-A165, VEGF-A183, VEGF-A189
and VEGF-A206. It is synthesized by various cell types,
including mast cells, smooth muscle cells of vascular
walls, macrophages, fibroblasts, neoplastic cells, cells
of endothelium, monocytes, keratinocytes,
eosinophiles and lymphocytes T [41]. VEGF-A plays a
key role in the process of angiogenesis [42].
VEGF-B in 88% resembles the structure of VEGF-
A and also participates in processes of angiogenesis
and neurogenesis [43-46].
VEGF-C is indispensable in embryonal develop-
ment in the process of formation of lymphatic vessels
[47]. It manifests a mitogenic and a protective role
related to both lymphatic and blood vessels [48]. A
pronounced expression of VEGF-C is noted in the
heart, placenta, muscles, ovaries, intestines and in cer-
tain tumours [49]. The factor is responsible also for
increases in permeability and diameter of lymphatic
vessels [50]. It seems to be of key importance in the
process of lymphangiogenesis [51].
VEGF-D is expressed in the lungs, skin, heart, skele-
tal muscles, alimentary tract and in certain tumours [52].
It stimulates growth and migration of lymphatic
endothelium cells [53]. Similarly to VEGF-C, VEGF-D
participates also in the process of lymphangiogenesis
[54]. 
VEGF-E, which till now has been located only in orf
viruses, may be involved in the process of angiogenesis
[55]. The orf virus, termed also the virus of ovine small-
pox, belongs to the family of Poxviridae. The family
encompasses large and structurally complex DNA
viruses with a strong immunogenic potential. 
The placenta growth factor (PIGF) fulfils an impor-
tant role in both physiological and pathological angio-
genesis. Similarly to VEGF it stimulates proliferation
of endothelial cells. Originally, the factor was isolated
for the first time from human placenta but later it was
identified also in various tumours [56].
VEGFR-3 (Vascular Endothelial Growth Factor
Receptor 3) proved to be the first specific receptor pro-
tein detected in lymphatic endothelium [57]. It fulfils
the role of a receptor for lymphatic vessel endothelial
growth factors VEGF-C and VEGF-D, belonging to
the IIIrd class of tyrosine receptors [53]. Activation of
VEGFR-3 by its ligands, VEGF-C and VEGF-D as
well as the subsequent activation of its intracellular
domain of tyrosine kinase stimulates proliferation of
lymphatic endothelial cells [8]. Activity of lymphan-
giogenesis taking advantage of the VEGFR-3/VEGF-
C/VEGF-D axis was demonstrated in numerous inves-
tigations both in vivo and in vitro [58]. On the other
hand, VEGFR-1 and VEGFR-2 receptors are charac-
teristic for endothelium of blood vessels. The VEGFR-
2 receptor serves as the most important transmitter of
signals in the process of angiogenesis but its presence
was demonstrated also in lymphatic cisternae and lym-
phatic capillaries in the course of lymphangiogenesis
[18]. The interaction between endothelial growth fac-
tors and VEGFR receptors have been presented by
several authors [11, 59, 60]. In our review we would
like to suggest a simple scheme of the above described
relationships (Fig. 2).
Lymphangiogenesis in malignant tumours 
The high mortality associated with neoplastic dis-
eases used to ascribed, first of all, to spread in the body
of neoplastic cells in the form of metastases. Clinical
and anatomopathological reports confirm that metas-
tases by lymphatic vessels to sentinel (regional) lymph
nodes represent the early manifestation of the disease
spread in cases of many solid tumours in humans [61].
Presence of neoplastic cells in the draining lymph
nodes represents a significant index in evaluation of
tumour advancement and in selection of the appropri-
ate surgery, chemotherapy and radiotherapy. As men-
tioned earlier, the discovery of lymphatic vessel mark-
ers promoted development of studies using experimen-
tal models which allow for isolation of lymphatic
endothelial cells. In recent years, increasing numbers
of reports have appeared related to the role of lym-
phangiogenesis in mammary cancer, cancers of pan-
creas, prostate, stomach, in melanoma and pulmonary
tumours as well as to growth factors specific for the
processes [62-67]. 
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Dissemination of neoplastic cells from the primary
tumour may take place by invasion of the local tissues,
by the networks of lymphatic and blood vessels and by
dissemination within body cavities. The most common
method involves development of metastases due to
spread of neoplastic cells with the circulating blood
and within lymphatic vessels [67]. Schematic presen-
tation of spread mechanisms and development of
metastases from the tumour cells is shown in Fig. 3. 
In 2005, He et al. [68] investigated the manner in
which neoplastic cells enter lymphatic vessels and
may form neoplastic metastases. The current concepts
related to the mechanisms of metastasis formation are
illustrated in Fig. 4A (in our own modification of the
concept given in [67]). The neoplastic cells and
macrophages which surround the tumour release
VEGF-C and VEGF-D [8]. Activation of VEGFR-3
receptor by its ligands, VEGF-C and VEGF-D, leads
to activation of its intracellular domain of tyrosine
kinase, which stimulates proliferation and migration of
lymphatic endothelial cells [69]. The mechanisms
which promote the invasion of lymphatic vessels by
neoplastic cells may include intra- and perineoplastic
lymphangiogenesis as well as interactions between
neoplastic cells and lymphatic endothelial cells (LEC).
They result in an increase in penetrability of lymphat-
ic vessels, altered adhesive properties of vascular
endothelial cells, in this way facilitating development
of metastases in lymph nodes [70].
The potential for inhibition of metastatic coloniza-
tion of lymph nodes by tumour cells by inhibition of
the VEGF-C/VEGF-D/ VEGFR-3 axis is shown in
Fig. 4B. However, investigations of He et al. [68]
demonstrated that inhibition of the VEGF-C/VEGF-D/
VEGFR-3 axis was not sufficient to block develop-
ment of metastases and the tumour cells still were
present in the lymph nodes. Therefore, it seemed pur-
poseful to inhibit lymphangiogenesis in parallel to
blocking of the direct invasion of neoplastic cells from
337Lymphangiogenesis in lung cancer
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(3): 337 (333-342) 
10.2478/v10042-009-0090-3
Fig. 2. Interactions between vasculoendothelial growth factors and
their VEGFR receptors (60) in modification of our own. VEGF
(VEGF-A) binds to VEGFR-1 and VEGFR-2. PIGF and VEGF-B
are specific ligands for VEGFR-1. VEGF-E activates VEGFR-2.
VEGF-C and VEGF-D interact with VEGFR-2 and VEGFR-3.
Fig. 3. Development of metastases (1) in continuity, in surround-
ing tissues, (2) by blood vessels, (3) by lymphatic vessels, (4) dis-
semination in body cavities (60, in modification of our own).
Fig. 4. A. Current concepts related to mechanisms in which neo-
plastic metastases develop using VEGFR-3/VEGF-C/VEGF-D
axis. B. Potential for inhibition of metastases to lymph nodes by
blocking VEGFR-3/VEGF-C/VEGF-D axis (67; in modification
of our own). 
the primary tumour [68]. Activation of the VEGF-
C/VEGF-D/VEGFR-3 axis increases motility and
invasiveness of neoplastic cells and in this way pro-
motes development of neoplastic metastases in several
types of tumours, e.g., in lung adenocarcinoma, can-
cers of mammary gland, neck, prostate and large intes-
tine [71]. Most of the reports documented positive cor-
relation noted between overexpression of VEGF-C and
VEGF-D on one hand and invasion of lymphatic ves-
sels, involvement of lymph nodes, development of dis-
tant metastases and an unfavourable clinical course on
the other in various histological types of malignant
tumours [72]. 
Also other lymphangiogenesis-stimulating factors
were described as factors which negatively affect the
course and prognosis in neoplastic diseases [65]. 
Cyclooxygenase 2 (COX-2) and its overexpression
are associated with an unfavourable course of gastric
as well as pulmonary adenocarcinoma and, in parallel,
they stimulate lymphangiogenesis [73,74]. Also
VEGF-C and COX-2 have been found to exhibit posi-
tive correlation with density of lymphatic microvessels
and the extent of invasion of lymphatic vessels by neo-
plastic cells in gastric cancer [75]. 
Fibroblast growth factor 2 (FGF-2) induces both
angiogenesis and lymphangiogenesis through the con-
trol of VEGF-C and VEGF-D expression, which has
been confirmed in animal experiments [76].
Angiopoetin-1 and insulin-like growth factor (IGF)
represent mediators in the action of VEGF-C/VEGF-
D/VEFGR-3 axis [77,78]. 
Even if VEFG-A plays a significant role in angio-
genesis, some investigations point also to effects of
VEGF-A on induction of lymphangiogenesis directly
through activation of VEGFR-2 and indirectly, induc-
ing an augmented secretion of VEGF-C and VEGF-D
by macrophages in vicinity of neoplastic cells [79]. In
view of the investigations it seems that treatment of
tumours might yield improved effects upon parallel
administration of VEGF-A/VEGFR-2 mechanism
blockers, e.g. Avastin, and inhibitors of VEGFR-3
/VEGF-C/VEGF-D/ axis [57]. Recent studies on ani-
mal models, related to fibrosarcoma have demonstrated
that platelet-derived growth factor (PDGF) induced
neoplastic lymphangiogenesis and is responsible for
development of intraneoplastic lymphatic vessels,
which augments their potential to form intraneoplastic
lymphatic vessels, thus stimulating their potential to
develop metastases in lymph nodes [80]. In view of the
above, extensive hope is linked to application of antag-
onists of platelet-derived growth factor, such as, e.g.,
Gleevec in treatment of neoplastic diseases [75]. 
Other new studies have shown that hepatocyte
growth factor (HGF) participates in lymphangiogene-
sis by stimulating growth of peritumoral lymphatics
(PTLs), due to activation of VEGFR-3 receptor [81]. 
Other currently conducted investigations also have
demonstrated that nitrogen oxide (NO) is produced
and released by cells of lymphatic endothelium and,
probably due to its effect on penetrability of lymphat-
ic endothelium, leads to stimulation of one of the iso-
forms of nitrogen oxide synthase (iNOS). In turn,
activity of nitrogen oxide synthase in a tumour has
been found to manifest positive correlation with
expression of VEGF-C and VEGF-D [82].
Lymphangiogenesis in lung cancer
Lung cancer represent one of the most frequent causes
of death due to neoplasia. Despite the progress in diag-
nosis and treatment prognosis in patients with lung
cancer remains poor. Among many prognostic indices
in non-small cell lung cancer presence of metastases to
lymph nodes remains to be of principal prognostic sig-
nificance [83]. Also, few data are available on mediat-
ing mechanisms in development of metastases to
lymph nodes in lung cancer. The role of lymphangio-
genesis in development of the tumour type continues
to be studied. Studies on animal models related to
breast and renal carcinomas unequivocally indicate
that an increase in the level of VEGF-C or VEGF-D
induces lymphangiogenesis [51,84]. Studies from the
recent few years have indicated a positive correlation
between expressions of VEGF-C/D and VEGFR-3 in
non-small cell lung cancer [85]. 
In lung adenocarcinoma increase in the level of
mRNA for VEGF-C is indicative of metastases to
lymph nodes [86]. Moreover, a significantly longer
survival has been shown in patients with non-small
cell lun cancer manifesting low expression of VEGF-
C as compared to patients with high expression of
VEGF-C [87]. 
In 2008 Kawai et al. [1] in patients with non-small
cell lung cancer detected significant role of VEGF-A
121 isoform in promotion of lymphangiogenesis in
sentinel lymph nodes situated most closely to the
tumour. In order to evaluate lymphangiogenesis in the
lymph nodes antibodies specific for LYVE-1 were
used. In such patients, the authors detected a signifi-
cantly elevated levels of LYVE-1 and VEGF-A 121 in
sentinel lymph nodes as compared to the other lymph
nodes. In the patients VEGF-A 121 was found to pro-
mote proliferation of lymphatic endothelium cells [1].
Moreover, the same authors detected a significant pos-
itive correlation between expression of VEGF-C and
VEGF-D on one hand and expression of LYVE-1
expression in sentinel lymph nodes with neoplastic
metastases. The relationship was absent from sentinel
lymph nodes free of metastases [1]. 
Also in the year of 2008 Kadota et al. [88] evaluated
lymphatic vessel density (LVD) and extent of invasion
to lymphatic vessels (LVI) using antibodies specific for
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D2-40 (an equivalent of podoplanin) in patients with
various types of non-small cell lung cancer. In the same
patients density of intra-tumour microvessels (MVD)
was also evaluated. A significantly higher lymphatic
vessel density (LVD) was detected in squamous cell car-
cinoma as compared to adenocarcinoma. Shorter sur-
vival of the patients was linked to high LVD and high
MVD. Lymphangiogenesis was found to be correlated
with a high LVD. The data indicated that LVD and
MVD represent independent prognostic indices in
patients with non-small cell lung cancer [88].
The till now obtained results allow to conclude that
high expression of VEGF-C correlates with presence
of metastases to lymph nodes and with poor prognosis
in patients with non-small cell lung cancer. The poor
prognosis in such patients is also linked to high densi-
ty of lymphatic vessels and a high density of intra-
tumour microvessels. 
Extensive hopes are associated also with drugs
which inhibit lymphangiogenesis. Hopefully, in future
improved results of pulmonary carcinoma treatment
will be obtained due to application of a combined
chemotherapy, consisting of, i.a., inhibitors of epider-
mal growth factor receptors and inhibitors of VEGFR-
3 receptor [89]. 
Inhibition of lymphangiogenesis
VEGFR-3 for VEGF represented the first to be described
specific receptor protein for lymphatic endothelium [57].
It plays role of a receptor for the lymphatic endothelium
growth factors, VEGF-C and VEGF-D. Recent investi-
gations on animal models unequivocally proved that an
increased level of VEGF-C and/or VEGF-D promotes
lymphangiogenesis in neoplastic diseases and a lym-
phatic vessel-mediated tumour spread to regional lymph
nodes. The phenomenon may be inhibited by blocking
VEGFR-3 receptor [92].
Application of a soluble form of the VEGFR-3
receptor in lung cancer reduces the amount of intra-
tumour lymphatic vessels as well as decreases fre-
quency of metastases to regional lymph nodes and to
the lungs [69,92,93]. Inhibitors of VEGFR-2 receptor
proved to function also as inhibitors of VEGFR-3
receptor, such as Surafenib (Nexavar, BAY 43-9006)
[89] and Cediranib (Recentin, AZD2171) [90] studied
on lung cancer, SU 11248, studied on renal carcinoma
[94]. Cediranib, examined by Heckman in 2008, sig-
nificantly inhibited both angiogenesis and lymphan-
giogenesis in experimental models with adenoviruses
[91]. MAZ 51 inhibited growth of breast cancer in
studies on animal models [95]. Promising results were
also obtained in studies on a recombined protein
received from adenoviruses, which affected expression
of the soluble form of VEGFR-3 receptor. The protein
helped to inhibit metastases to lymph nodes and to
decrease the amount of peri-tumour lymphatic vessels
in mice [51,96]. In studies on animals with tumours
secreting recombined VEGF-D, in which monoclonal
antibodies to VEGF-D were used, which blocked lig-
and binding to both VEGFR-2 and VEGFR-3, the
inhibited processes involved angiogenesis, lymphan-
giogenesis and spread of lymphatic vessel-mediated
tumour metastases [84,97]. Also in recent years clini-
cal studies succeeded in inhibiting growth of metasta-
tic colonic and anal cancer due to application of
Avastin preparation (Bevacizumab), the monoclonal
antibody specific for VEGF (an inhibitor of angiogen-
esis) [98]. Duration of an average survival till progres-
sion of the disease and mean survival of the patients
were found to be extended in the patients. 
Summary 
The problems which remain to be clarified include
molecular mechanisms of lymphangiogenesis, speci-
ficity of growth factors, markers of lymphatic vessels
and numerous phenomena responsible for tumour
growth and its spread by lymphatic vessels. Recogni-
tion of angiogenesis and lymphangiogenesis and
design of drugs which effectively inhibit the processes
may significantly improve results of therapy in neo-
plastic diseases.
In recent years, lymphangiogenesis in pulmonary
cancer constitutes a topic of intense studies. In the
non-small cell lung cancer expressions of VEGF-C/D
and of VEGFR-3 have been found to be positively cor-
related with each other.
A significantly abbreviated survival is noted in lung
cancer patients with high expression of VEGF-C.
Investigations conducted in 2008 have demonstrated
positive correlation between expression of VEGF-C
and VEGF-D on one hand and expression of LYVE-1
in sentinel lymph nodes with metastases of neoplastic
cells on the other in patients with non-small cell lung
cancer [1]. Also, high density of lymphatic vessels and
a high density of intra-tumour microvessels have been
demonstrated to represent independent unfavourable
prognostic indices in patients with non-small cell lung
cancer [88].
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